

**DISEASE BURDEN**

In 2022, 39 million people globally were living with HIV and 1.3 million people became newly infected, most of which occurred in LMICs.

**CLINICAL RELEVANCE**

GS-4182 is a lenacapavir prodrug with improved bioavailability and potential for oral weekly administration. It is likely to be used to complement oral weekly regimens in combination with ARVs like islatravir or GS-1720.

**INTELLECTUAL PROPERTY LANDSCAPE**

**SERVICE DELIVERY ENABLERS**

Assessment in progress

**REGULATORY**

Assessment in progress

**MANUFACTURING**

Assessment in progress

**MARKET**

Assessment in progress

**GS-4182**  
HIV  
TREATMENT  
*Gilead*